In vitro and in vivo Antimicrobial Activities of Ceftazidime/Avibactam Alone or in Combination with Aztreonam Against Carbapenem-Resistant Enterobacterales

References

• Hu F, Guo Y, Yang Y, et al. Resistance reported from China antimicrobial surveillance network (CHINET) in 2018. Eur J Clin Microbiol Infect Di. 2019;38(12):2275–2281. doi:10.1007/s10096-019-03673-1
   PubMed Web of Science ®Google Scholar
• Seo H, Lee SC, Chung H, et al. Clinical and microbiological analysis of risk factors for mortality in patients with carbapenem-resistant Enterobacteriaceae bacteremia. Int J Antimicrob Agents. 2020;56(4):106126. doi:10.1016/j.ijantimicag.2020.106126
   PubMed Web of Science ®Google Scholar
• Sun J, Wang B, Warden AR, et al. Overcoming multidrug-resistance in bacteria with a two-step process to repurpose and recombine established drugs. Anal Chem. 2019;91(21):13562–13569. doi:10.1021/acs.analchem.9b02690
   Web of Science ®Google Scholar
• Seok H, Choi JY, Wi YM, et al. Fosfomycin resistance in Escherichia coli isolates from South Korea and in vitro activity of fosfomycin alone and in combination with other antibiotics. Antibiotics. 2020;9(3):112. doi:10.3390/antibiotics9030112
   Web of Science ®Google Scholar
• Isber C, Stockman DL, Daoud Z. Quadruple-checkerboard: a modification of the three-dimensional checkerboard for studying drug combinations. J Vis Exp. 2021;173:e62311.
   Google Scholar
• Zhang W, Guo Y, Li J, et al. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase–producing Klebsiella pneumoniae. Antimicrob Resist Infect Control. 2018;7(1):142. doi:10.1186/s13756-018-0435-9
   Web of Science ®Google Scholar
• Richter SN, Frasson I, Bergo C, et al. Transfer of KPC-2 Carbapenemase from Klebsiella pneumoniae to Escherichia coli in a patient: first case in Europe. J Clin Microbiol. 2011;49(5):2040–2042. doi:10.1128/JCM.00133-11
   Web of Science ®Google Scholar
• Bleichenbacher S, Stevens M, Zurfluh K, et al. Environmental dissemination of carbapenemase-producing Enterobacteriaceae in rivers in Switzerland. Environ Pollut. 2020;265(Pt B):115081. doi:10.1016/j.envpol.2020.115081
   Web of Science ®Google Scholar
• Suay-Garcia B, Perez-Gracia MT. Present and future of Carbapenem-resistant Enterobacteriaceae (CRE) Infections. Antibiotics. 2019;8(3):122. doi:10.3390/antibiotics8030122
   Web of Science ®Google Scholar
• Han R, Shi Q, Wu S, et al. Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) among carbapenem-resistant Enterobacteriaceae isolated from adult and children patients in China. Front Cell Infect Microbiol. 2020;10:314. doi:10.3389/fcimb.2020.00314
   PubMed Web of Science ®Google Scholar
• Veeraraghavan B, Shankar C, Karunasree S, et al. Carbapenem resistant Klebsiella pneumoniae isolated from bloodstream infection: Indian experience. Pathog Glob Health. 2017;111(5):240–246. doi:10.1080/20477724.2017.1340128
   PubMed Web of Science ®Google Scholar
• Galani I, Karaiskos I, Karantani I, et al. Epidemiology and resistance phenotypes of carbapenemase-producing Klebsiella pneumoniae in Greece, 2014 to 2016. Euro Surveill. 2018;23(31). doi:10.2807/1560-7917.ES.2018.23.30.1700775
   Google Scholar
• Maraki S, Mavromanolaki VE, Moraitis P, et al. Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-beta-lactamase-producing Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis. 2021;40(8):1755–1759. doi:10.1007/s10096-021-04197-3
   PubMed Web of Science ®Google Scholar
• Meini S, Viaggi B, Tascini C, Mono V. combo regimens with novel beta-lactam/beta-lactamase inhibitor combinations for the treatment of infections due to carbapenemase-producing Enterobacterales: insights from the literature. Infection. 2021;49(3):411–421. doi:10.1007/s15010-021-01577-x
   PubMed Web of Science ®Google Scholar
• Hakeam HA, Alsahli H, Albabtain L, et al. Effectiveness of ceftazidime-avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteremia. Int J Infect Dis. 2021;109:1–7. doi:10.1016/j.ijid.2021.05.079
   PubMed Web of Science ®Google Scholar
• Di Pilato V, Aiezza N, Viaggi V, et al. KPC-53, a KPC-3 variant of clinical origin associated with reduced susceptibility to ceftazidime-avibactam. Antimicrob Agents Chemother. 2020;65(1):e01429. doi:10.1128/AAC.01429-20
   PubMed Web of Science ®Google Scholar
• Li D, Liao W, Huang H, et al. Emergence of hypervirulent ceftazidime/avibactam-resistant Klebsiella pneumoniae isolates in a Chinese tertiary hospital. Infect Drug Resist. 2020;13(2673–2680). doi:10.2147/IDR.S257477
   Web of Science ®Google Scholar
• Wang Y, Wang J, Wang R, et al. Resistance to ceftazidime-avibactam and underlying mechanisms. J Glob Antimicrob Resist. 2020;22:18–27. doi:10.1016/j.jgar.2019.12.009
   PubMed Web of Science ®Google Scholar
• Wenzler E, Deraedt MF, Harrington AT, et al. Synergistic activity of ceftazidime-avibactam and aztreonam against serine and metallo-β-lactamase-producing gram-negative pathogens. Diagn Microbiol Infect Dis. 2017;88(4):352–354. doi:10.1016/j.diagmicrobio.2017.05.009
   PubMed Web of Science ®Google Scholar
• Yao H, Liu J, Jiang X, et al. Analysis of the clinical effect of combined drug susceptibility to guide medication for carbapenem-resistant Klebsiella pneumoniae patients based on the Kirby-Bauer disk diffusion method. Infect Drug Resist. 2021;14:79–87. doi:10.2147/IDR.S282386
   Web of Science ®Google Scholar
• Falcone M, Menichetti F, Cattaneo D, et al. Pragmatic options for dose optimization of ceftazidime/avibactam with aztreonam in complex patients. J Antimicrob Chemother. 2021;76(4):1025–1031. doi:10.1093/jac/dkaa549
   PubMed Web of Science ®Google Scholar
• Yasmin M, Fouts DE, Jacobs MR, et al. Monitoring ceftazidime-avibactam and aztreonam concentrations in the treatment of a bloodstream infection caused by a multidrug-resistant Enterobacter sp. carrying both Klebsiella pneumoniae Carbapenemase–4 and New Delhi Metallo-β-Lactamase–1. Clin Infect Dis. 2020;71(4):1095–1098. doi:10.1093/cid/ciz1155
   PubMed Web of Science ®Google Scholar
• Vena A, Giacobbe DR, Castaldo N, et al. Clinical experience with ceftazidime-avibactam for the treatment of infections due to multidrug-resistant gram-negative bacteria other than carbapenem-resistant enterobacterales. Antibiotics. 2020;9(2):71. doi:10.3390/antibiotics9020071
   Web of Science ®Google Scholar
• Cultrera R, Libanore M, Barozzi A, et al. Ceftolozane/tazobactam and ceftazidime/avibactam for multidrug-resistant gram-negative infections in immunocompetent patients: a single-center retrospective study. Antibiotics. 2020;9(10):640. doi:10.3390/antibiotics9100640
   Web of Science ®Google Scholar
• Nwankwo L, Butt Z, Schelenz S. Experience of Ceftazidime/avibactam in a UK tertiary cardiopulmonary specialist center. Expert Rev Anti Infect Ther. 2021;19(1):101–108. doi:10.1080/14787210.2020.1810568
   PubMed Web of Science ®Google Scholar
• Kuang H, Zhong C, Wang Y, et al. Clinical characteristics and outcomes of patients with multidrug-resistant Gram-negative bacterial infections treated with ceftazidime/avibactam. J Glob Antimicrob Resist. 2020;23:404–407. doi:10.1016/j.jgar.2020.10.023
   Web of Science ®Google Scholar
• Castanheira M, Mills JC, Costello SE, et al. Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of beta-lactamase-producing strains. Antimicrob Agents Chemother. 2015;59(6):3509–3517. doi:10.1128/AAC.00163-15
   PubMed Web of Science ®Google Scholar